The entire population of The Gambia is at high risk of malaria and transmission is intense for most of the year. The annual reported number of malaria cases in 2017 was 75,559 with 54 deaths.
**Malaria**

**Progress**
The Gambia has secured resources to finance the malaria commodities required for 2019. The country has procured sufficient LLINs and carried out IRS to sustain 100% operational coverage. The Gambia has enhanced the tracking and accountability mechanisms for malaria with the development of a Malaria Control and Elimination Scorecard. The Gambia has decreased the estimated malaria mortality rate by more than 40% since 2010.

**Impact**
The annual reported number of malaria cases in 2017 was 75,559 with 54 deaths.

**Key Challenge**
- The country has funding gaps preventing the further scale up of IRS.

**Previous Key Recommended Action**
The Gambia has responded positively to the malaria recommended action addressing reporting on the status of insecticide resistance monitoring to WHO and continues to track progress as these reported actions are implemented.

**RMNCAH and NTDs**

**Progress**
The country has achieved high coverage of the tracer RMNCAH interventions postnatal care and DPT3 vaccination. The Gambia has significantly enhanced the tracking and accountability mechanisms with the development of the Reproductive, Maternal, Newborn, Child and Adolescent Health Scorecard.

Progress in addressing Neglected Tropical Diseases (NTDs) in The Gambia is measured using a composite index calculated from preventive chemotherapy coverage achieved for schistosomiasis, soil transmitted helminths, and trachoma. Preventive chemotherapy coverage in Gambia is high for trachoma (100%), schistosomiasis (85%) and low for soil transmitted helminths (44%). The NTD preventive chemotherapy coverage index for Gambia in 2017 is 72, which represents a very substantial increase compared with the 2016 index value (8).

**Previous Key Recommended Actions**
The Gambia has responded positively to the RMNCAH recommended action addressing the low coverage of ARTs and vitamin A and continues to track progress as these actions are implemented.